Literature DB >> 26722543

Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas.

Longxin Wang1, Haibing Hu2, Feng Tian3, Wenquan Zhou1, Shuigen Zhou1, Jiandong Wang4.   

Abstract

The receptor tyrosine kinase of EphA2 has been shown frequently overexpressed in various types of human carcinomas, which implicated that it plays important roles in carcinogenesis. Although EphA2 protein expression has been investigated in many types of human carcinomas, the relationship between the expression of EphA2 protein in clear cell renal cell carcinoma was not well documented. In the present study, using specific anit-EphA2 polyclonal antibody and immunohistochemistry, we evaluated EphA2 protein expression levels in clear cell RCC specimens surgically resected from 90 patients. Our results shows that EphA2 protein was positively expressed in all normal renal tubes of 90 samples (100%, 3+), which was expressed at low levels in renal cortex but high levels in the collecting ducts of the renal medulla and papilla. EphA2 was negatively or weakly expressed in 30 out of 90 samples (33.3%, 0/1+), moderately expressed in 24 samples (26.7%, 2+) and strongly expressed in 36 samples (40%, 3+). Expression of EphA2 was positively associated with age (P=0.029), tumor diameters (P<0.001) and Fuhrman nuclear grade (P<0.001). Our results indicate that EphA2 variably expressed in clear cell renal cell carcinomas. High expression of EphA2 was more often found in big size and high nuclear grade tumors, which indicated EphA2 protein may be used as a new marker for the prognosis of clear cell renal cell carcinoma.

Entities:  

Keywords:  EphA2; Fuhrman nuclear grade; clear cell renal cell carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26722543      PMCID: PMC4680488     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  37 in total

1.  VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.

Authors:  Francesca Lessi; Chiara Maria Mazzanti; Sara Tomei; Claudio Di Cristofano; Andrea Minervini; Michele Menicagli; Alessandro Apollo; Lorenzo Masieri; Paola Collecchi; Riccardo Minervini; Marco Carini; Generoso Bevilacqua
Journal:  Med Oncol       Date:  2014-01-21       Impact factor: 3.064

2.  The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors:  Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

3.  Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).

Authors:  Rashmi Bhat Singh; Pratibha S Amare Kadam
Journal:  Urol Oncol       Date:  2011-10-01       Impact factor: 3.498

4.  Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.

Authors:  Christopher J Herrem; Tomohide Tatsumi; Kathleen S Olson; Keisuke Shirai; James H Finke; Ronald M Bukowski; Ming Zhou; Amy L Richmond; Ithaar Derweesh; Michael S Kinch; Walter J Storkus
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

5.  Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells.

Authors:  Sahiti Chukkapalli; Mohamed Amessou; Ashok K Dilly; Hafedh Dekhil; Jing Zhao; Qiang Liu; Alex Bejna; Ron D Thomas; Sudeshna Bandyopadhyay; Tarek A Bismar; Daniel Neill; Laurent Azoulay; Gerald Batist; Mustapha Kandouz
Journal:  Exp Cell Res       Date:  2013-11-06       Impact factor: 3.905

6.  High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia.

Authors:  Guangyuan Zeng; Zhiqiang Hu; Michael S Kinch; Chong-Xian Pan; David A Flockhart; Chinghai Kao; Thomas A Gardner; Shaobo Zhang; Lang Li; Lee Ann Baldridge; Michael O Koch; Thomas M Ulbright; John N Eble; Liang Cheng
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

7.  EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma.

Authors:  Tatsuya Miyazaki; Hiroyuki Kato; Minoru Fukuchi; Masanobu Nakajima; Hiroyuki Kuwano
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

8.  Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.

Authors:  Tomohide Tatsumi; Christopher J Herrem; Walter C Olson; James H Finke; Ronald M Bukowski; Michael S Kinch; Elena Ranieri; Walter J Storkus
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

9.  Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma.

Authors:  O Straume; L A Akslen
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

10.  A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.

Authors:  Aaron Petty; Eugene Myshkin; Haina Qin; Hong Guo; Hui Miao; Gregory P Tochtrop; Jer-Tsong Hsieh; Phillip Page; Lili Liu; Daniel J Lindner; Chayan Acharya; Alexander D MacKerell; Eckhard Ficker; Jianxing Song; Bingcheng Wang
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

View more
  4 in total

1.  Receptor Tyrosine Kinase EphB3: a Prognostic Indicator in Colorectal Carcinoma.

Authors:  Zhuoqi Xuan; Jianming Huang; Lin Gao; Yong Wang; Jiandong Wang; Yueming Sun
Journal:  Pathol Oncol Res       Date:  2018-12-07       Impact factor: 3.201

2.  ACAT1 and Metabolism-Related Pathways Are Essential for the Progression of Clear Cell Renal Cell Carcinoma (ccRCC), as Determined by Co-expression Network Analysis.

Authors:  Liang Chen; Tianchen Peng; Yongwen Luo; Fenfang Zhou; Gang Wang; Kaiyu Qian; Yu Xiao; Xinghuan Wang
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

3.  Identification of Biomarkers Associated With Pathological Stage and Prognosis of Clear Cell Renal Cell Carcinoma by Co-expression Network Analysis.

Authors:  Liang Chen; Lushun Yuan; Kaiyu Qian; Guofeng Qian; Yuan Zhu; Chin-Lee Wu; Han C Dan; Yu Xiao; Xinghuan Wang
Journal:  Front Physiol       Date:  2018-04-18       Impact factor: 4.566

4.  RNA editing affects cis-regulatory elements and predicts adverse cancer survival.

Authors:  Yuan-Ming Wu; Yan Guo; Hui Yu; Tao Guo
Journal:  Cancer Med       Date:  2021-07-28       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.